These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21537159)

  • 21. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
    Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
    Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients.
    Suh DC; Lee DH; McGuire M; Kim CM
    Curr Med Res Opin; 2011 Aug; 27(8):1623-33. PubMed ID: 21696266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
    LaCivita KA; Villarreal G
    Curr Med Res Opin; 2002; 18(6):363-70. PubMed ID: 12442884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
    Freed MI; Ratner R; Marcovina SM; Kreider MM; Biswas N; Cohen BR; Brunzell JD;
    Am J Cardiol; 2002 Nov; 90(9):947-52. PubMed ID: 12398960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China].
    Zhu XX;
    Zhonghua Nei Ke Za Zhi; 2003 Sep; 42(9):636-9. PubMed ID: 14514393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.
    Ko SH; Song KH; Ahn YB; Yoo SJ; Son HS; Yoon KH; Cha BY; Lee KW; Son HY; Kang SK
    Metabolism; 2003 Jun; 52(6):731-4. PubMed ID: 12800099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
    Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
    Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
    Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An overweight diabetic does not tolerate metformin. Insulin sensitizer can be prescribed alone, too].
    MMW Fortschr Med; 2003 Dec; 145(49):58. PubMed ID: 14963999
    [No Abstract]   [Full Text] [Related]  

  • 33. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.
    Yu D; Murdoch SJ; Parikh SJ; Marcovina SM; Cobitz A; Chen H; Brunzell JD
    Diab Vasc Dis Res; 2006 Dec; 3(3):189-96. PubMed ID: 17160915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein effects of different thiazolidinediones in clinical practice.
    Ovalle F; Bell DS
    Endocr Pract; 2002; 8(6):406-10. PubMed ID: 15251829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Derosa G; Gaddi AV; Piccinni MN; Salvadeo S; Ciccarelli L; Fogari E; Ghelfi M; Ferrari I; Cicero AF
    Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R; Xu Y; Abbadessa M;
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes.
    Gómez-Perez FJ; Fanghänel-Salmón G; Antonio Barbosa J; Montes-Villarreal J; Berry RA; Warsi G; Gould EM
    Diabetes Metab Res Rev; 2002; 18(2):127-34. PubMed ID: 11994904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus.
    Atamer Y; Atamer A; Can AS; Hekimoğlu A; Ilhan N; Yenice N; Koçyiğit Y
    Braz J Med Biol Res; 2013 Jun; 46(6):528-32. PubMed ID: 23802228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
    Chaudhuri A; Rosenstock J; DiGenio A; Meneghini L; Hollander P; McGill JB; Dandona P; Ilgenfritz J; Riddle M
    Diabetes Metab Res Rev; 2012 Mar; 28(3):258-67. PubMed ID: 22081557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.